@article{JTD18260,
author = {Cesare Gridelli and Francesca Casaluce and Assunta Sgambato and Giovanni Palazzolo and Paolo Maione},
title = {J-ALEX trial will crown alectinib as the standard choice for anaplastic lymphoma kinase positive untreated non-small cell lung cancer patients?},
journal = {Journal of Thoracic Disease},
volume = {10},
number = {1},
year = {2018},
keywords = {},
abstract = {About 4–5% of advanced non-small cell lung cancer (NSCLC) patients are diagnosed with an oncogene- addicted disease, due to the presence of echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) fusion gene (1). Before August 2011, chemotherapy was the only option for those patients.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/18260}
}